Особливості впливу метаболічного синдрому на агресивність перебігу раку передміхурової залози

Summary. The purpose of the study was to investigate the specifics of the clinical and morphological course of prostate cancer (PCa) in patients with metabolic syndrome (MS) and its influence on the spread of the metastatic process. Materials and methods. The study included 79 patients with locally advanced PCa who underwent inpatient treatment in the period from 2015 to 2020 in plastic and reconstructive department of National cancer institute of Ukraine and undergo further outpatient observation, diagnosis and treatment during the time before the development of bone metastasis (BM) from the moment of radical prostatectomy (RP), among which MS was diagnosed in 40 (50.6%) and absent in 39 (49.4%). The average age of the patients was: 69 (59–80) years. Patients participated in the study with existing MS were divided into 2 studied groups: 17 (21.5%) with moderate risk (Grade group 2, 3) and 23 (29.1%) with high risk (Grade group 4, 5) of disease progression, in contrast to patients without MS: 20 (25.3%) with Grade group 2, 3 and 19 (24.1%) with Grade group 4, 5. The average initial level of total PSA in patients with MS and Grade group 2, 3 was: 16.35 ng/ml, Grade group 4, 5 — 23.75 ng/ml. In patients without MS with Grade group 2, 3 — 14 ng/ml, Grade group 4, 5 — 21.45 ng/ml. Results. Among 79 study participants, after RP, 35 (44.3%) were diagnosed with the development of bone and visceral metastases, in contrast to 44 (55.7%) without metastases. Among 35 patients with the development of BM — 27 (77.1%) with MS, 8 (22.9%) — no signs of MS. BM was combined with visceral metastases in 17 (48.5%) patients, MS was found in most cases of this cohort of 11 (64.7%) patients. BM in the subgroup of moderate risk (Gleason